|
|
x | |
Preface |
|
xxi | |
Part 1 Assessing and utilizing the diagnostic or prognostic power of biomarkers |
|
|
Evidence-based medicine: evaluation of biomarkers |
|
|
3 | (13) |
|
|
Development of biomarkers: the industrial perspective |
|
|
16 | (8) |
|
|
Statistical approaches to rational biomarker selection |
|
|
24 | (8) |
|
|
Using intelligent systems in clinical decision support |
|
|
32 | (13) |
|
Part 2 Biomarkers of kidney disease and dysfunction |
|
|
Biomarkers in renal disease |
|
|
45 | (11) |
|
|
The genetics of renal disease |
|
|
56 | (10) |
|
|
|
Early markers of nephrotoxicity for environmental and occupational monitoring |
|
|
66 | (10) |
|
|
The early detection of renal impairment in diabetes mellitus. The case for microalbuminuria and other biomarkers |
|
|
76 | (23) |
|
Part 3 Biomarkers of bone disease and dysfunction |
|
|
Bone turnover markers in clinical practice |
|
|
99 | (16) |
|
|
|
Biomarkers of bone formation |
|
|
115 | (7) |
|
|
|
|
|
|
|
Biochemical markers of bone resorption |
|
|
122 | (11) |
|
|
The clinical application of biomarkers in osteoporosis |
|
|
133 | (7) |
|
|
Sources of preanalytical variability in the measurement of biochemical markers of bone turnover |
|
|
140 | (19) |
|
|
Genetic approaches to the study of complex diseases: osteoporosis |
|
|
159 | (8) |
|
Part 4 Biomarkers of liver disease and dysfunction |
|
|
Biomarkers of hepatic disease |
|
|
167 | (10) |
|
|
The immunogenetics of metabolic liver disease |
|
|
177 | (13) |
|
|
Toxicogenetic markers of liver dysfunction |
|
|
190 | (9) |
|
|
Prognosis and management of patients with acute liver failure |
|
|
199 | (12) |
|
|
Biomarkers in artificial and bioartificial liver support |
|
|
211 | (10) |
|
|
Prognostic markers in liver disease |
|
|
221 | (7) |
|
|
Apoptosis: biomarkers and the key role of mitochondria |
|
|
228 | (11) |
|
|
Liver regeneration: mechanisms and markers |
|
|
239 | (5) |
|
|
|
Determinants of responses to viruses and self in liver disease |
|
|
244 | (12) |
|
|
|
IL-6-type cytokines and signalling in inflammation |
|
|
256 | (9) |
|
|
|
|
|
|
|
|
|
|
Part 5 Biomarkers of gastrointestinal disease and dysfunction |
|
|
Biomarkers in gastrointestinal disease |
|
|
265 | (7) |
|
|
Tumour markers in gastrointestinal disease |
|
|
272 | (9) |
|
|
|
Markers of malabsorption: coeliac disease |
|
|
281 | (10) |
|
|
|
Part 6 Biomarkers in toxicology |
|
|
Genomics and biomarkers in toxicology |
|
|
291 | (8) |
|
|
|
Protein profiling and proteomic databases |
|
|
299 | (14) |
|
|
|
|
|
|
Biomarkers for evaluating the safety of genetically modified foods |
|
|
313 | (12) |
|
|
|
Part 7 Biomarkers of cardiovascular disease and dysfunction |
|
|
The impact of biochemical tests on patient management |
|
|
325 | (9) |
|
|
Cardiac natriuretic peptides in risk assessment of patients with acute myocardial infarction or congestive heart failure |
|
|
334 | (11) |
|
|
Serum markers of inflammation and cardiovascular risk |
|
|
345 | (10) |
|
|
The clinical significance of markers of coagulation in acute coronary syndromes |
|
|
355 | (10) |
|
|
|
Endothelin: what does it tell us about myocardial and endothelial dysfunction? |
|
|
365 | (9) |
|
|
Homocysteine: a reversible risk factor for coronary heart disease |
|
|
374 | (5) |
|
|
Matrix metalloproteinases and their tissue inhibitors |
|
|
379 | (12) |
|
|
|
|
Part 8 Biomarkers of neurological disease and dysfunction |
|
|
Biomarkers of neurodegenerative disorders |
|
|
391 | (7) |
|
|
Traumatic brain injury: assessment by biochemical serum markers |
|
|
398 | (8) |
|
|
|
An overview of S-100β as a clinically useful biomarker of brain tissue damage |
|
|
406 | (9) |
|
|
Part 9 Biomarkers in transplantation |
|
|
Monitoring heart and lung transplant patients |
|
|
415 | (8) |
|
|
Monitoring liver transplant recipients |
|
|
423 | (10) |
|
|
Chronic allograft damage index as a surrogate marker for chronic allograft rejection |
|
|
433 | (9) |
|
|
|
|
|
|
Advances in pharmacodynamic biomarkers for monitoring the response to immunosuppressive drug therapy |
|
|
442 | (9) |
|
|
The use of biomarkers for monitoring the response to immunosuppressive drug therapy |
|
|
451 | (10) |
|
|
Post-transplantation bone disease |
|
|
461 | (6) |
|
|
Molecular diagnosis of cytomegalovirus disease |
|
|
467 | (7) |
|
|
|
|
Diagnosis and monitoring of inflammatory events in transplant recipients |
|
|
474 | (9) |
|
|
|
|
|
Index |
|
483 | |